Merck & Co. and NicOx Extend Research Collaboration
News Nov 03, 2005
NicOx S.A. has announced the extension of its research collaboration agreement with Merck & Co., Inc.
The purpose of the agreement, signed in August 2003, is to jointly evaluate selected proprietary NicOx nitric oxide-donating compounds in an undisclosed therapeutic area.
While the research was initially focused on one class of compounds, the two companies have agreed to broaden the field of investigation based on joint pre-clinical work conducted to date.
Additional pre-clinical studies will be initiated to identify potential lead candidates for development. Merck will make a payment to NicOx in connection with this extension of the agreement.
Merck exercised its exclusive option to negotiate for a license, development and commercialization agreement during the second quarter of 2005.
Michele Garufi, Chairman and CEO of NicOx, commented, “We look forward to continuing our collaboration with Merck. We are very pleased with the progress of this important research program, which suggests that nitric oxide-donation could provide potential benefits in an area of considerable medical need.”
“The conclusion of any future licensing agreement is of course dependent on successful results from the new research program and the agreement of contractual terms. NicOx and Merck expect to conclude this process during 2006.”
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE